PFS

Open Access
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2– advanced breast cancer
Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li and Binghe Xu

Cancer Biology & Medicine October 2024, 21 (10) 934-950; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0204
You have access
Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer
Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng and Kai Li

Cancer Biology & Medicine August 2022, 19 (8) 1249-1258; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0727

Main menu